

ECUSTEC Baseline Form

| FORM TO BE COMPLETED FROM THE CASE NOTES <u>AFTER</u> RANDOMISATION AND <u>BEFORE</u> THE ALLOCATED TREATMENT IS ADMINISTERED | | | | | | | | |
|---|---|--|--|--|--|--|--|--|
| Trial number: Site Name: | Date of Birth: / (mon/yyyy) | | | | | | | |
| Part A: Recent Medical History | | | | | | | | |
| Date of working diagnosis of HUS: (dd/mon/yyyy) | Time of working diagnosis: h h : m m 24 hour clock | | | | | | | |
| Date of arrival at the renal unit: (dd/mon/yyyy) | Time of arrival: h h:m m 24 hour clock | | | | | | | |
| Date seen by paediatric nephrologist: (dd/mon/yyyy) | Time Seen: h h : m m 24 hour clock | | | | | | | |
| Eligible on arrival at the renal unit? Yes No | * | | | | | | | |
| *If no, state date and time eligibility confirmed: (dd/mon/yyyy) hh h:mm 24 hour clock | | | | | | | | |
| Clinical Symptom for STEC HUS diagnosis (within la | st 14 days) Date of onset | | | | | | | |
| Diarrhoea: Yes * No | (dd/mon/yyyy) | | | | | | | |
| *If yes, bloody diarrhoea?: Yes No | | | | | | | | |
| STEC positive: Yes* No Unknown | Household contact STEC positive: Yes No | | | | | | | |
| *If STEC positive, results assessed by: PCR Stool Serology Serotype if known: | | | | | | | | |
| Central Nervous System | | | | | | | | |
| Any Central Nervous System symptoms in the 48 hours | prior to randomisation? Yes* No | | | | | | | |
| *If yes, tick all that apply: | | | | | | | | |
| Altered consciousness (Agitation, irritability, hallucination | ns, confusion, excessive drowsiness) Yes No | | | | | | | |
| Single seizure | Yes No | | | | | | | |
| Two or more seizures 24 hours apart | Yes No | | | | | | | |
| Clinical Data | | | | | | | | |
| Blood pressure (average of 3 recordings): / | mmHg | | | | | | | |
| Did the child receive RRT? | | | | | | | | |
| *If no, was the estimated urine output <0.5ml/kg/hr for lo | onger than 12 hours? Yes No Not Known | | | | | | | |
| Part B: Signs and Symptoms for Meningoco | occal Disease and Septicaemia | | | | | | | |
| Are parents/patient/guardian in possession of the ECUS Card? Yes No | TEC Meningitis Warning Card and ECUSTEC Patient Study | | | | | | | |
| Part C: Protocol-mandated Therapy (prior to r | andomisation) | | | | | | | |
| Has trial-mandated antibiotic cover commenced? (penicill | in, erythromycin) Yes* No | | | | | | | |
| *If yes, which trial-mandated antibiotic has been comme | nced? Penicillin Erythromycin Other* | | | | | | | |
| *If other specify | Dose T mg Frequency | | | | | | | |

| Trial | Number: | | | | Dat | e of Birth: | | _/ | (ma | on/yyyy) |
|--|---|-------------|----------|-----|--------------------|-------------|--------------|----------|--------------|----------|
| Part D: Vaccination Status Yes* No *If yes, Date if known | | | | | | | | | ite if known | |
| Has the patient received conjugate meningococcal ACWY vaccine | | | | | | | | | (dd/mon/y | VVV) |
| (Nimenrix or Menveo)? Has the patient received Meningococcal B vaccine (Bexsero™) as part of the ECUSTEC trial? | | | | | | | | | (dd/mon/y | |
| Has t | Has the patient received Meningococcal B vaccine (Bexsero™) as part of the UK immunisation programme? | | | | | | | | | ууу) |
| | Unsure if immunised as part of the UK immunisation programme | | | | | | | | | |
| Part E:Medical Therapy (7 days prior to randomisation date) | | | | | | | | | | |
| Paracetamol? Yes No Ibuprofen? Yes No | | | | | | | | | | |
| Codeine? Yes No Loperamide? Yes No Other anti-motility agent? Yes No | | | | | | | | | | |
| \Mere | any other antibio | tics given? | Yes | | No | Specify | / antibic | tic aive | an: | |
| | Date: (dd/mon | | | | 1140 | | | | n/yyyy) | |
| Start | Date. (dd/111011) | / | | | | Stop D | ale. (u | u/11101 | 1/ y y y y) | |
| Part F(a): Bloods and Biochemistry To be completed from the case notes. Please state the readings for the parameters below, for the closest set of values prior to IMP administration. | | | | | | | | | | |
| | Paramet | Reading W | | | Within L Yes | | rmal R No | ange No | ot Done | |
| Neutr | ophils | | | | 10 ⁹ /L | | | | | |
| White blood cell count | | | | | 10 ⁹ /L | | | | | |
| C-reactive protein | | | | | mg/L | | | | | |
| Lactate Dehydrogenase (LDH) | | | | U/L | | | | ı | | |
| Creatinine | | | umol/L | | | | | | | |
| Glucose | | | . mmol/L | | | | | | | |
| Amyla | ase | | | | U/L | | | | | |
| Alanine transaminase U | | | | U/L | | | | | | |
| Urea | | | | | mmol/L | | | | | |
| Sodium mmol/L | | | | | mmol/L | | | | | |
| Plasma C3 concentration g/L | | | | g/L | | | | | | |
| Plasma C4 Concentration g/L | | | | | | | | | | |
| Part F(b): Bloods and Biochemistry, Regular Platelet Readings To be completed from the case notes. Please state the reading for the closest value prior to IMP administration | | | | | | | | | | |
| Day Recorded? Date of Readin | | day of r | | | day of re | _ | | | | |
| 4 🗆 🗆 | | | | | | Yes | | No | | |
| 1 | | (dd/mon/yy | yy) | | 10 ⁹ /L | | | | | |

Confidential once completed

Please answer all the questions

EudraCT number: 2016-000997-39

| EudraCT number: 2016-000997-39 | | | (| Confidential ond | ce complete | ed | Please answer <u>all</u> the questions | | | |
|---|--------|--------------------|------------|-----------------------------|-------------|-----------------|--|--|--|--|
| Trial Number: | | | | | Date of | Birth: | / | (mon/yyyy) | | |
| Part G: Quality of Life Questionnaires (refer to Appendix 3 for age suitable version) | | | | | | | | | | |
| Have the standardised, parent/patient completed, questionnaires been completed at Baseline? | | | | | | | | | | |
| Form | CHU-9D | | | Peds-QL | | | | | | |
| Baseline | | Yes | No | Ye | Yes No | | | | | |
| Part H: Samples (Please indicate which baseline samples have been collected and complete the samples log in the site file) | | | | | | | | | | |
| Optional/Not Optional | | Sample Typ | е | Consent giv optional sar | | Was the staken? | ample | Notes/problem with sample preparation, if any: | | |
| Not optional | | Blood EDTA | — genetics | | | Yes | No | | | |
| Optional | | Blood (EDTA) | | Yes | No | Yes | No | | | |
| Optional | | Blood (co-culture) | | Yes | No | Yes | No | | | |
| Optional | | Urine | | Yes | No No | Yes | No | | | |
| <u>In addition</u> to the trial mandated samples referred to above, please remember to forward stool and serum samples to the PHE/SERL laboratories (as appropriate) in accordance with routine practice. | | | | | | | | | | |
| Part I: Form Completion | | | | | | | | | | |
| Completed by (name): | | | | | | | | | | |
| Signed:Date Completed: (dd/mon/yyyy) | | | | | | | | | | |
| PI Name: | | | | | | | | | | |
| PI Confirmation Signature: Date Completed: (dd/mon/yyyy) | | | | | | | | | | |